english.prescrire.org > Spotlight > 100 most recent > GLP-1 agonists in pregnancy: poorly elucidated risks that warrant a highly cautious approach

Spotlight

Every month, the subjects in Prescrire’s Spotlight.

100 most recent :  1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90

GLP-1 agonists in pregnancy: poorly elucidated risks that warrant a highly cautious approach

 Adverse effects  Dulaglutide, exenatide, liraglutide, lixisenatide, semaglutide and tirzepatide are all teratogenic and fetotoxic in animal models. What about in humans? This article summarises the data on in-utero exposure to GLP-1 agonists identified through our literature search. Do these drugs increase the risk of malformations or have other fetal, neonatal or obstetrical consequences? And what are the long-term effects on children exposed in utero?
Full article available for download by subscribers

 ©Prescrire 1 March 2026

Source: "GLP-1 agonists in pregnancy: poorly elucidated risks that warrant a highly cautious approach" Prescrire Int 2026; 35 (279): 75-77. Subscribers only.

Filet

Enjoy full access to Prescrire International, and support independent information

 
Share
Share on Facebook  
 
 
See also:
 
"GLP-1 agonists:
depression, suicidal
thoughts or behaviour?"
Prescrire Int 2024;
33 (258): 103-105.
Subscribers only